Literature DB >> 19718643

The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.

Javier Murillas1, Antonio Rimola, Montserrat Laguno, Elisa de Lazzari, Javier Rascón, Fernando Agüero, José L Blanco, Eduardo Moitinho, Asunción Moreno, José M Miró.   

Abstract

End-stage liver disease (ESLD) has become the main cause of mortality in patients coinfected by human immunodeficiency virus (HIV) and hepatitis B virus or hepatitis C virus in developed countries. The aim of this study was to describe the natural history of and prognostic factors for ESLD, with particular attention paid to features affecting liver transplantation. This was a prospective cohort study in 2 Spanish community-based hospitals performed between 1999 and 2004. One hundred four consecutive patients with cirrhosis and a first clinical decompensation of their chronic liver disease or hepatocellular carcinoma were included in the study. During a median follow-up of 10 months (endpoint: death, liver transplantation, or the last checkup date), 61 patients (59%) died. The probability of mortality (Kaplan-Meier method) at 1, 2, and 3 years was 43% [95% confidence interval (CI), 34%-60%], 59% (95% CI, 48%-70%), and 70% (95% Cl, 59%-81%), respectively. In a multivariate analysis, the Model for End-Stage Liver Disease (MELD) score and the inability to reach an undetectable plasma HIV-1 RNA viral load at any time during follow-up were the only variables independently associated with the risk of death (P < 0.001). Fifteen (14%) of the 104 patients were accepted for liver transplantation, although only 5 underwent the procedure, and 10 died while on the waiting list. The waiting list mortality rate in patients with a MELD score < 20 and in patients with a MELD score >20 was 58% and 100%, respectively (median follow-up, 5 months). In conclusion, HIV-1-infected patients with ESLD, especially those with poorly controlled HIV and a high MELD score, have a poor short-term outcome. The MELD score may be useful in deciding whether to indicate liver transplantation in these patients. However, because only a small proportion of the patients in this study were considered candidates for liver transplantation and most died while on the waiting list, few received a transplant. (c) 2009 AASLD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19718643     DOI: 10.1002/lt.21735

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  13 in total

1.  Ventilator associated pneumonia following liver transplantation: Etiology, risk factors and outcome.

Authors:  Antonio Siniscalchi; Lucia Aurini; Beatrice Benini; Lorenzo Gamberini; Stefano Nava; Pierluigi Viale; Stefano Faenza
Journal:  World J Transplant       Date:  2016-06-24

2.  Clinical characteristics of human immunodeficiency virus patients being referred for liver transplant evaluation: a descriptive cohort study.

Authors:  V Martel-Laferrière; A Michel; S Schaefer; S Bindal; K Bichoupan; A D Branch; S Huprikar; T D Schiano; P V Perumalswami
Journal:  Transpl Infect Dis       Date:  2015-06-15       Impact factor: 2.228

3.  Human immunodeficiency virus and liver disease forum 2012.

Authors:  Kenneth E Sherman; David Thomas; Raymond T Chung
Journal:  Hepatology       Date:  2013-11-22       Impact factor: 17.425

Review 4.  Solid Organ Transplantation in HIV-Infected Recipients: History, Progress, and Frontiers.

Authors:  William A Werbel; Christine M Durand
Journal:  Curr HIV/AIDS Rep       Date:  2019-06       Impact factor: 5.071

5.  Liver transplant outcomes in HIV+ haemophilic men.

Authors:  M V Ragni; M E Devera; M E Roland; M Wong; V Stosor; K E Sherman; D Hardy; E Blumberg; J Fung; B Barin; D Stablein; P G Stock
Journal:  Haemophilia       Date:  2012-07-05       Impact factor: 4.287

Review 6.  Outcomes and management of viral hepatitis and human immunodeficiency virus co-infection in liver transplantation.

Authors:  Stephen E Congly; Karen E Doucette; Carla S Coffin
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

Review 7.  Role of liver transplantation in human immunodeficiency virus positive patients.

Authors:  Deepak Joshi; Kosh Agarwal
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

8.  Survival in HIV-positive transplant recipients compared with transplant candidates and with HIV-negative controls.

Authors:  Michelle E Roland; Burc Barin; Shirish Huprikar; Barbara Murphy; Douglas W Hanto; Emily Blumberg; Kim Olthoff; David Simon; William D Hardy; George Beatty; Peter G Stock
Journal:  AIDS       Date:  2016-01-28       Impact factor: 4.177

Review 9.  Pros and cons of liver transplantation in human immunodeficiency virus infected recipients.

Authors:  Umberto Baccarani; Elda Righi; Gian Luigi Adani; Dario Lorenzin; Alberto Pasqualucci; Matteo Bassetti; Andrea Risaliti
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

10.  MELD Score Kinetics in Decompensated HIV+/HCV+ Patients: A Useful Prognostic Tool (ANRS HC EP 25 PRETHEVIC Cohort Study).

Authors:  Moana Gelu-Simeon; Tatiana Bayan; Maria Ostos; Faroudy Boufassa; Elina Teicher; Jean-Marc Steyaert; Inga Bertucci; Rodolphe Anty; Georges-Philippe Pageaux; Laurence Meyer; Jean-Charles Duclos-Vallée
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.